<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="119220">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01750970</url>
  </required_header>
  <id_info>
    <org_study_id>2009/34</org_study_id>
    <nct_id>NCT01750970</nct_id>
  </id_info>
  <brief_title>Endoscopic Resection of Bladder Tumors</brief_title>
  <official_title>Endoscopic Rescetion of High Grade(TA, T1, Cis)Non-muscle Invasive Bladder Tumors: Modification of Usual Management of This Resection by Using the Blue Light and Evaluation of the Outcome: Should we Maintain the Dogma of Second Endoscopic Resection as a Principle?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hopital Foch</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hopital Foch</source>
  <oversight_info>
    <authority>France: Direction Générale de la Santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To confirm the benefit of endoscopic resection under fluorescence and blue light of high
      grade non-muscle invasive bladder tumor, and verifying if the second endoscopic resection
      recommended nowadays can be deleted.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Anticipated">February 2013</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of extra lesions revealed by blue light compared to the resection performed in white light</measure>
    <time_frame>2 to 6 weeks after resection</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">166</enrollment>
  <condition>Bladder Tumor</condition>
  <arm_group>
    <arm_group_label>Resection under blue light</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Resection under white light</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Endoscopic resection under blue light (Hexvix®)</intervention_name>
    <description>Endoscopic resection</description>
    <arm_group_label>Resection under blue light</arm_group_label>
    <arm_group_label>Resection under white light</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - 18 year-old and older male and female subjects having high grade non-muscle invasive
        bladder tumor, with urinary cytology , imaging examination (Ultrasound, urography, or
        scan) and endoscopic examination

        Exclusion Criteria:

        - Less than 18 years of age, and having no:

          -  Non-muscle invasive tumor, and of low grade.

          -  Bladder tumor infiltrating the muscular layer shown by pre-operative test, with
             absence of urinary cytology

          -  No blue light source in sustainable way
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henry BOTTO, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hôpital FOCH  40, rue Worth 92150 Suresnes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Henry BOTTO, MD</last_name>
    <email>h.botto@hopital-foch.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital FOCH</name>
      <address>
        <city>Suresnes</city>
        <zip>92150</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henry BOTTO, MD</last_name>
      <email>h.botto@hopital-foch.org</email>
    </contact>
    <investigator>
      <last_name>Henry BOTTO, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2009</verification_date>
  <lastchanged_date>December 13, 2012</lastchanged_date>
  <firstreceived_date>December 11, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hopital Foch</investigator_affiliation>
    <investigator_full_name>Liliane FALGERE</investigator_full_name>
    <investigator_title>Administrative coordinator clinical research unit</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
